Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team

Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Because of the...

Descripción completa

Detalles Bibliográficos
Autores principales: McCabe, Colleen, Wright, Hillary, Polson, Kathleen, Wagner, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560410/
https://www.ncbi.nlm.nih.gov/pubmed/37805596
http://dx.doi.org/10.1186/s13023-023-02926-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560410/
https://www.ncbi.nlm.nih.gov/pubmed/37805596
http://dx.doi.org/10.1186/s13023-023-02926-9

Ejemplares similares